Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death. [Crit Care. 2006]
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
Friedrich JO, Adhikari NK, Meade MO. Crit Care. 2006; 10(6):427.
Review Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis. [Drug Saf. 2007]
Review Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D. Drug Saf. 2007; 30(11):995-1010.
Drotrecogin alfa (activated) in severe sepsis. [N Engl J Med. 2006]
Drotrecogin alfa (activated) in severe sepsis.
Baillie JK, Murray G. N Engl J Med. 2006 Jan 5; 354(1):94-6; author reply 94-6.
Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). [Pharmacotherapy. 2005]
Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST, Isakow W, Shannon W, Kollef MH. Pharmacotherapy. 2005 Jan; 25(1):26-34.
Review Drotrecogin alfa (activated) in the treatment of severe sepsis. [Expert Rev Anti Infect Ther. 2006]
Review Drotrecogin alfa (activated) in the treatment of severe sepsis.
Vincent JL. Expert Rev Anti Infect Ther. 2006 Aug; 4(4):537-47.

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death. [Crit Care. 2006]
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
Friedrich JO, Adhikari NK, Meade MO. Crit Care. 2006; 10(6):427.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Drotrecogin alfa (activated): current evidence supports treatment for severe sep...
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.
Crit Care. 2006 ;10(5):424.

PubMed
Erythropoietin therapy for acute stroke is both safe and beneficial.
Erythropoietin therapy for acute stroke is both safe and beneficial.
Mol Med. 2002 Aug ;8(8):495-505.

PubMed
The assessment of four different methods to verify tracheal tube placement in th...
The assessment of four different methods to verify tracheal tube placement in the critical care setting.
Anesth Analg. 1999 Apr ;88(4):766-70.

PubMed
RIFLE classification is predictive of short-term prognosis in critically ill pat...
RIFLE classification is predictive of short-term prognosis in critically ill patients with acute renal failure supported by extracorporeal membrane oxygenation.
Nephrol Dial Transplant. 2006 Oct ;21(10):2867-73. Epub 2006 Jun 24 .

PubMed
The Brain Trauma Foundation. The American Association of Neurological Surgeons. ...
The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Critical pathway for the treatment of established intracranial hypertension.
J Neurotrauma. 2000 Jun-Jul ;17(6-7):537-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.